Discover

Back to filter

Related topics

High quality Bioluminescence and X-Ray analysis in lung squamous cell carcinoma

Spectral Instruments Imaging

Jul 21, 2021

Spectral Instruments Imaging provides unrivaled sensitivity for bioluminescence,...

Top 10 Pharma companies have chosen CYTEK for their flow cytometry facility

Cytek Biosciences

Jul 15, 2021

6 of Top 10 Pharma Companies (Based on total group revenues) have chosen CYTEK - full...

Webinar recording: Autofluorescence management - the power of Spectral Flow Cytometry

Cytek Biosciences

Jul 15, 2021

One of the key advantages of spectral flow cytometry is its ability to extract sample...

Webinar recording: Super-Resolution imaging of Chromatin organization in health and disease

ONI

Jul 9, 2021

Understanding how cells organize the array of components within their membranous confines can not only provide insight...

Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles

Spectral Instruments Imaging

Jul 3, 2021

Overactivation of the PI3K/mTOR signaling has been identified in non-Hodgkin’s lymphoma....

Quantitative two-photon microscopy imaging analysis of human skin

IVIM Technology

Jul 1, 2021

Transdermal skin delivery is a method to transport various topical formulations to a deeper skin layer non-invasively....

Show all topics (10)

In vivo fluorescence imaging in mouse models of metastatic pheochromocytomas and paragangliomas

Mar 6, 2017

Pheochromocytomas (PHEOs) and extra-adrenal paragangliomas (PGLs) are rare adrenaline-producing tumors. The two tumor types are closely related and are distinguished primarily by their location: pheochromocytomas occur in the center of the adrenal glands while extra-adrenal paragangliomas originate in the paraganglia of the sympathetic nervous system (most commonly in the abdomen). Extra-adrenal paragangliomas are less common, but more likely to be malignant, than pheochromocytomas.
Diagnosis of metastatic PHEOs/PGLs is difficult and tends to rely on identification of adrenaline/noradrenaline production in areas where adrenaline/noradrenaline is not normally produced. Furthermore, such metastases are notoriously difficult to treat. A variety of chemotherapy combinations and radiotherapy are used as palliative treatment, but complete remission is rare.
Consequently, the mouse pheochromocytoma mCherry tumor allograft model was developed, which is functionally similar to human PHEO/PGLs. This mouse model has recently been used to assess the value of the [177Lu]Lu-DOTA-(Tyr3)octreotate (DOTATATE), a labeled somatostatin receptor analog, as a targeted therapy for metastatic PHEO/PGLs in man. And this study confirms that the mCherry model is a uniquely powerful tool for evaluating therapeutic or diagnostic agents that specifically target the somatostatin-2 receptor.

Read more

 

Scientific paper
Application

Brand profile

Bruker Biospin

Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey